New clues explain how pancreatic tumors evade the immune system

Home Research Strategic Research Program Pancreatic Cancer News New clues explain how pancreatic tumors evade the immune system

Research in the News

New clues explain how pancreatic tumors evade the immune system

There are two related papers published in the June 12, 2012 edition of the prestigious journal Cancer Cell, describing how pancreatic tumors are able to secrete factors to prevent the patient’s immune system from recognizing or attacking the cancer cells.

Research for the first article took place in the New York University laboratory of Dafna Bar-Sagi, PhD. Dr. Bar-Sagi received a 2008 Pilot Grant from the Pancreatic Cancer Action Network, and this funding was cited as partially supporting this study. She is also a longstanding member of our Scientific Advisory Board, a past Chair, and currently serving as Interim Chair. The second article is out of the laboratory of Robert Vonderheide, MD, DPhil at the University of Pennsylvania. Dr. Vonderheide recently joined the Pancreatic Cancer Action Network’s Scientific Advisory Board. In addition, Dr. Vonderheide’s work is in collaboration with Ben Stanger, MD, PhD, recipient of the 2007 Ralph H. Hruban, MD – Pancreatic Cancer Action Network – AACR Career Development Award. The two research teams communicated to share results and coordinate complementary publication of their work.

Both articles report that pancreatic tumors secrete a protein called GM-CSF (granulocyte-macrophage colony-stimulating factor). Pancreatic tumors are known to be surrounded and infiltrated by a dense, complex tissue known as the tumor microenvironment. The research teams discovered in mouse models of pancreatic cancer that one of the roles of GM-CSF is to recruit cells to the microenvironment that impede an immune response against the tumor. They also demonstrated that the secretion of GM-CSF is dependent on mutant K-Ras, the most commonly mutated protein in pancreatic tumors.

The interdependence of pancreatic tumors and their microenvironment is an important subject for future research. The results from Drs. Bar-Sagi and Vonderheide published here suggest that blocking the production of GM-CSF may facilitate an immune response against the tumor. Further experiments will be necessary to determine whether this may be a feasible therapeutic approach.

Click here and here to see the scientific abstracts of both articles.
Click here for the NYU press release and here for the Penn press release.

Wage Hope With Us

Join us to make a difference for pancreatic cancer patients.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2020 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.